DNA sequencing

Nextech AR Announces Record $6.7 Million 3D Model Purchase Order From a NASDAQ 100 Technology Company

Retrieved on: 
Tuesday, October 18, 2022
Metaverse, Software, Other Retail, Online Retail, Internet, Department Stores, Electronic Commerce, Technology, Artificial Intelligence, Retail, Web3, Other Technology, Home Goods, LinkedIn, FSE, Education, Commerce, N29, 2D, 170, Augmented reality, Growth, Robotics, Machine learning, E-commerce, YouTube, AR, VCM, Solution, NASDAQ, 3D, Contract, Social media, Twitter, Instagram, Technology, ROI, Industrial, Student, Social, Blockchain, Company, Industry, AI, Legislation, CSE, NTAR, Technology company, Phrase, DNA sequencing, Iveco Bus, Artificial intelligence, Forward-looking statement, Arit Okpo, Calendar, Nex Entertainment, Television, 3D printing, Public relations, Metaverse, Facebook, Amazon

(Nextech or the Company) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), a Metaverse Company and leading provider of augmented reality (AR) experience technologies, wayfinding technologies and 3D model services is pleased to announce it has received its single largest purchaser order to date of $6.7 million from a NASDAQ 100 Technology Company.

Key Points: 
  • (Nextech or the Company) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), a Metaverse Company and leading provider of augmented reality (AR) experience technologies, wayfinding technologies and 3D model services is pleased to announce it has received its single largest purchaser order to date of $6.7 million from a NASDAQ 100 Technology Company.
  • With the previously announced $700,000 3D model order to be delivered in Q4, 2022 the total new orders recently announced equals $7.4 million.
  • These new 3D model orders set the stage for record growth in its 3D modeling business for the foreseeable future.
  • While $6.7 million is the most substantial 3D modeling order Nextech AR has received to date, the Company is still in negotiations for additional significant 3D modeling contracts from large enterprise customers, which it expects to announce shortly.

Pharmaceutical Industry Oncology Veteran Rohit Borker to join AESARA as VP, Oncology.

Retrieved on: 
Monday, October 17, 2022
Research, Women, Other Health, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Other Science, LinkedIn, VP, OBC, Physical Sciences-Oncology Centers, Neoplasm, Patient, Twitter, ICER, Precision medicine, DNA sequencing, Aesara, NGS, Contract, CEO, Economics, Corporate title, RWE, VBP, HTA, Solution, Medical imaging, Oncology

AESARA is pleased to announce the appointment of Rohit Borker as VP, Oncology, at AESARA, a digital-forward market access agency that develops innovative and trusted solutions to power transformative market access.

Key Points: 
  • AESARA is pleased to announce the appointment of Rohit Borker as VP, Oncology, at AESARA, a digital-forward market access agency that develops innovative and trusted solutions to power transformative market access.
  • Rohit has completed multiple Value Based Pricing (VBP) initiatives and HTA models to influence drug pricing at C-Suite levels, Outcomes- and Value-based Contracts (OBC/VBC) with multiple organized payer systems.
  • AESARA is a market access agency with a focused purpose to impact healthcare decision-making to improve peoples lives.
  • Established in 2016, we are a woman and minority-owned company with biopharma seasoned industry professionals in the U.S., Canada, and Europe.

Embark Launches First-Of-Its-Kind Age Test To Accurately Determine Dog's Calendar Age

Retrieved on: 
Tuesday, October 4, 2022
Veterinary medicine, Forbes, Veterinarian, Time, Learning, Research, Life, Genetics, Health, Cornell University College of Veterinary Medicine, Multimedia, Diet, Cornell University College of Agriculture and Life Sciences, View, Longevity, Embark Veterinary, Ageing, DNA methylation, Partnership, DNA sequencing, Exercise, Patient, Methylation, Microarray, Love, DNA, Dog, Vaccine, Animal, Illumina, Embark

BOSTON, Oct. 4, 2022 /PRNewswire/ -- Embark Veterinary, Inc., a global leader in dog health and genetics, today announced the launch of its Age Test. A first-of-its-kind product in the dog DNA industry, the Age Test uses a unique Embark-designed algorithm to measure a dog's age. The test relies on the cutting-edge field of epigenetics — the study of how external factors can change the way genes work — to estimate when a dog was born.

Key Points: 
  • A first-of-its-kind product in the dog DNA industry, the Age Test uses a unique Embark-designed algorithm to measure a dog's age.
  • The ultimate goal of the Age Test is to empower dog owners with the knowledge they need to provide personalized pet care.
  • Embark's Age Test estimates a dog's age by utilizing a beadchip technology that focuses on DNA methylation patterns.
  • Ultimately, data generated by the Embark Age Test will fuel future research on aging and epigenetics.

PathoQuest Announce the Opening of its New U.S. Facility

Retrieved on: 
Tuesday, October 4, 2022
Stem Cells, Biometrics, Biotechnology, Pharmaceutical, Health, Medical Devices, Genetics, Other Health, Vaccine, Time, GMP, Technology, General manager, Industry, CEO, Multimedia, NGS, Safety, USD, Method, DNA sequencing, Publication, Fine chemical, EUR

The establishment of the Wayne facility has been led by Dr. Colette Ct, the Chief Portfolio Officer and General Manager of PathoQuests U.S. operations.

Key Points: 
  • The establishment of the Wayne facility has been led by Dr. Colette Ct, the Chief Portfolio Officer and General Manager of PathoQuests U.S. operations.
  • Over the next 18 months the Wayne facility is planning to expand the number of employees to 20 as testing volume begins to ramp.
  • About PathoQuest: With over 20 peer reviewed publications on NGS applications in biosafety testing, PathoQuest is a leading expert in the provision of GMP NGS based biosafety testing.
  • PathoQuest is headquartered in Paris, France, and has worked with over 100 of the top biopharmaceutical companies globally.

Global Genome Sequencing Market Report 2022: Pharmaceutical Evolution Drives Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, General Health, Cancer, Government, Conditional sentence, Vaccination, Technology, Gene, Drug discovery, CAGR, Degenerative disease, PCR, Microarray, COVID-19, National Institutes of Health, Infection, Health, Growth, RNA, Application, DNA sequencing, International Nucleotide Sequence Database Collaboration, Diagnosis, National, DNA, Therapy, Genome, Vaccine, Antibiotics

Global genome sequencing market is anticipated to grow with an impressive CAGR during the forecast years on the grounds of growing technological advancement in genetic sequencing and bioinformatics.

Key Points: 
  • Global genome sequencing market is anticipated to grow with an impressive CAGR during the forecast years on the grounds of growing technological advancement in genetic sequencing and bioinformatics.
  • Surge in the demand for the advanced pharmaceuticals and evolving infectious diseases further drive the growth of the global genome sequencing market in the upcoming five years.
  • With consistent supply of financial funds from the government and higher research scope in the technology also supports the growth of the global genome sequencing market in the next five years.
  • Advancement in the biotechnological procedures and microbiology studies add to the growth of the global genome sequencing market in the upcoming five years.

STRmix Will Interpret DNA Evidence for Mississippi Office of Forensic Laboratories

Retrieved on: 
Thursday, September 22, 2022
LR, Probability, Weather, FST, ESR, Homicide, Engineering, Database, Office, LRS, Violent crime, FBI, Computational biology, Sexual assault, SNP, Tobacco, Technology, Environmental science, FRSNZ, New Zealand Institute, ATF, Death, SIDS, NGS, Network on a chip, DNA sequencing, DNA, Physics, Forensic science, Clark R. Bavin National Fish and Wildlife Forensic Laboratory, Department of Science and Technology (India), Mutation, Federal Bureau of Investigation, Suicide, STR, Kinship, Private investigator, Risk management, Dietary supplement, Firearm, Research

WASHINGTON, Sept. 22, 2022 /PRNewswire-PRWeb/ -- The Mississippi Office of Forensic Laboratories is the latest U.S. forensic lab to use STRmix™ forensic software in its scientific testing of crime scene evidence.

Key Points: 
  • WASHINGTON, Sept. 22, 2022 /PRNewswire-PRWeb/ -- The Mississippi Office of Forensic Laboratories is the latest U.S. forensic lab to use STRmix forensic software in its scientific testing of crime scene evidence.
  • Unlike traditional DNA analysis methods, STRmix is able to resolve mixed DNA profiles that previously would have been dismissed as too complex or degraded to interpret.
  • "Investing in the Mississippi Office of Forensic Laboratories has always been important.
  • The Office of Forensic Laboratories is comprised of the Mississippi Forensics Laboratory and the Office of the State Medical Examiner.

Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration

Retrieved on: 
Tuesday, September 20, 2022
CNV Public, Precision medicine, Cdx, Twitter, Infection, SNV calling from NGS data, FDA, Food, Liquid biopsy, LinkedIn, Gene, Urine, Review, DNA sequencing, Nucleic acid thermodynamics, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Diagnosis, Assay, De novo, NGS, RNA, Research, DNA, Silicon, GLOBE, HIV disease progression rates, Pharmaceutical industry, Medical imaging

The PredicineCARE cfDNA Assay is being developed to identify biomarker-eligible cancer patients with select indications who may benefit from treatment with targeted therapy.

Key Points: 
  • The PredicineCARE cfDNA Assay is being developed to identify biomarker-eligible cancer patients with select indications who may benefit from treatment with targeted therapy.
  • We are excited about FDAs decision to grant Breakthrough Device designation to the PredicineCARE cfDNA Assay, said Shidong Jia, Predicines Founder and Global CEO.
  • This is a significant milestone achievement in our journey to advancing liquid biopsy precision medicine and accelerating accessibility for cancer patients.
  • We look forward to further developing the PredicineCARE cfDNA Assay as a potential companion diagnostic test under the Breakthrough Devices Program.

Florida Cancer Specialists & Research Institute Celebrates Addition of Next-Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care

Retrieved on: 
Tuesday, September 6, 2022
FACP, Gene, Therapy, Doctor of Philosophy, Associate, News, NGS, Genetic testing, Society, FCS, Physician, DNA sequencing, University of Florida Cancer and Genetics Research Complex, U.S. News & World Report, GLOBE, Health, Genetics, Immunotherapy, ASCO, LLC, Cancer, Clinical trial, American Society of Clinical Oncology, Patient, Pharmaceutical industry, Medicine, Illumina, MD

Fort Myers, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the addition of genomic testing capabilities at its Next Generation Sequencing (NGS) laboratory in Fort Myers last week with a ribbon-cutting ceremony.

Key Points: 
  • Fort Myers, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the addition of genomic testing capabilities at its Next Generation Sequencing (NGS) laboratory in Fort Myers last week with a ribbon-cutting ceremony.
  • This advanced form of genetic testing can detect oncogenic mutations in hundreds of different genes derived from tumor cells simultaneously.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

Element Biosciences Welcomes Former ThermoFisher Executive Shelly Peariso to their Growing Commercial Team

Retrieved on: 
Thursday, September 1, 2022
Technology, Applied Biosystems, Research, Shelly, ABI Solid Sequencing, SAN, Capillary electrophoresis, Thermo Fisher Scientific, Thomas Jefferson University, Volleyball, DNA sequencing, Multimedia, Element, Industry, Lake Superior State University, Video game, Fine chemical, Biology

Shelly Peariso has been a life science and clinical sales executive for more than 20 years.

Key Points: 
  • Shelly Peariso has been a life science and clinical sales executive for more than 20 years.
  • Shelly started her sequencing career at Applied Biosystems in 2005 selling Capillary Electrophoresis and then transitioned to selling Next Generation Sequencing when SOLiD was introduced to the market.
  • After years of incremental progress, Element Biosciences has brought exponential thinking back to the field," said Shelly Peariso, Vice President of Sales.
  • Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets.

Lexogen Introduces RiboCop rRNA Depletion Kit for Yeast - a new library prep kit that enables efficient removal of rRNA and other transcripts

Retrieved on: 
Thursday, September 1, 2022
Yeast, RNA, RNA-Seq, RNA transfection, Transcriptome, DNA sequencing, Vaccine

VIENNA, Sept. 1, 2022 /PRNewswire/ -- Lexogen, a transcriptomics and Next-Generation Sequencing company announced the release of the new RiboCop rRNA Depletion Kit for Yeast today.

Key Points: 
  • VIENNA, Sept. 1, 2022 /PRNewswire/ -- Lexogen, a transcriptomics and Next-Generation Sequencing company announced the release of the new RiboCop rRNA Depletion Kit for Yeast today.
  • The new RiboCop rRNA Depletion Kit for Yeast enables our customers to sequence what matters most of all by ensuringefficient removal of rRNA.
  • RiboCop's rRNA depletion technology is based on hybridization of rRNA to specifically designed oligos and removal with magnetic beads.
  • RiboCop is well established for Human/Mouse/Rat rRNA depletion,combined Human/Mouse/Rat rRNA and globin mRNA depletion, and fordepletion of bacterial samples .